Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266

Watchlist Manager
Suzhou Zelgen Biopharmaceuticals Co Ltd Logo
Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266
Watchlist
Price: 64.04 CNY -4.28% Market Closed
Market Cap: 17B CNY
Have any thoughts about
Suzhou Zelgen Biopharmaceuticals Co Ltd?
Write Note

Intrinsic Value

The intrinsic value of one Suzhou Zelgen Biopharmaceuticals Co Ltd stock under the Base Case scenario is 57.58 CNY. Compared to the current market price of 64.04 CNY, Suzhou Zelgen Biopharmaceuticals Co Ltd is Overvalued by 10%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
57.58 CNY
Overvaluation 10%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Suzhou Zelgen Biopharmaceuticals Co Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for Suzhou Zelgen Biopharmaceuticals Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about Suzhou Zelgen Biopharmaceuticals Co Ltd?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Suzhou Zelgen Biopharmaceuticals Co Ltd

Provide an overview of the primary business activities
of Suzhou Zelgen Biopharmaceuticals Co Ltd.

What unique competitive advantages
does Suzhou Zelgen Biopharmaceuticals Co Ltd hold over its rivals?

What risks and challenges
does Suzhou Zelgen Biopharmaceuticals Co Ltd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide P/S
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide P/E
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide P/OCF
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide P/FCFE
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide P/B
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide EV/S
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide EV/GP
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide EV/EBITDA
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide EV/EBIT
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide EV/OCF
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide EV/FCFF
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide EV/IC
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Show me price targets
for Suzhou Zelgen Biopharmaceuticals Co Ltd made by professional analysts.

What are the Revenue projections
for Suzhou Zelgen Biopharmaceuticals Co Ltd?

How accurate were the past Revenue estimates
for Suzhou Zelgen Biopharmaceuticals Co Ltd?

What are the Net Income projections
for Suzhou Zelgen Biopharmaceuticals Co Ltd?

How accurate were the past Net Income estimates
for Suzhou Zelgen Biopharmaceuticals Co Ltd?

What are the EPS projections
for Suzhou Zelgen Biopharmaceuticals Co Ltd?

How accurate were the past EPS estimates
for Suzhou Zelgen Biopharmaceuticals Co Ltd?

What are the EBIT projections
for Suzhou Zelgen Biopharmaceuticals Co Ltd?

How accurate were the past EBIT estimates
for Suzhou Zelgen Biopharmaceuticals Co Ltd?

Compare the revenue forecasts
for Suzhou Zelgen Biopharmaceuticals Co Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Suzhou Zelgen Biopharmaceuticals Co Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Suzhou Zelgen Biopharmaceuticals Co Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Suzhou Zelgen Biopharmaceuticals Co Ltd compared to its peers.

Compare the P/E ratios
of Suzhou Zelgen Biopharmaceuticals Co Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Suzhou Zelgen Biopharmaceuticals Co Ltd with its peers.

Analyze the financial leverage
of Suzhou Zelgen Biopharmaceuticals Co Ltd compared to its main competitors.

Show all profitability ratios
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide ROE
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide ROA
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide ROIC
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide ROCE
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide Gross Margin
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide Operating Margin
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide Net Margin
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide FCF Margin
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Show all solvency ratios
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide D/E Ratio
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide D/A Ratio
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide Interest Coverage Ratio
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide Altman Z-Score Ratio
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide Quick Ratio
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide Current Ratio
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Provide Cash Ratio
for Suzhou Zelgen Biopharmaceuticals Co Ltd.

What is the historical Revenue growth
over the last 5 years for Suzhou Zelgen Biopharmaceuticals Co Ltd?

What is the historical Net Income growth
over the last 5 years for Suzhou Zelgen Biopharmaceuticals Co Ltd?

What is the current Free Cash Flow
of Suzhou Zelgen Biopharmaceuticals Co Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Suzhou Zelgen Biopharmaceuticals Co Ltd

Current Assets 2.7B
Cash & Short-Term Investments 2.4B
Receivables 143.2m
Other Current Assets 186m
Non-Current Assets 393.9m
Long-Term Investments 6m
PP&E 299.7m
Intangibles 59.5m
Other Non-Current Assets 28.7m
Current Liabilities 1.2B
Accounts Payable 124.4m
Accrued Liabilities 71m
Short-Term Debt 915.4m
Other Current Liabilities 58.3m
Non-Current Liabilities 363.5m
Long-Term Debt 29.2m
Other Non-Current Liabilities 334.3m
Efficiency

Earnings Waterfall
Suzhou Zelgen Biopharmaceuticals Co Ltd

Revenue
407.2m CNY
Cost of Revenue
-31.3m CNY
Gross Profit
375.9m CNY
Operating Expenses
-673.8m CNY
Operating Income
-297.9m CNY
Other Expenses
67m CNY
Net Income
-230.9m CNY

Free Cash Flow Analysis
Suzhou Zelgen Biopharmaceuticals Co Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

Suzhou Zelgen Biopharmaceuticals Co Ltd's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional Revenue Growth Forecast
ROIC is Increasing
36/100
Profitability
Score

Suzhou Zelgen Biopharmaceuticals Co Ltd's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Suzhou Zelgen Biopharmaceuticals Co Ltd's solvency score is 70/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Negative Net Debt
Short-Term Solvency
Low D/E
70/100
Solvency
Score

Suzhou Zelgen Biopharmaceuticals Co Ltd's solvency score is 70/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Suzhou Zelgen Biopharmaceuticals Co Ltd

Wall Street analysts forecast Suzhou Zelgen Biopharmaceuticals Co Ltd stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Suzhou Zelgen Biopharmaceuticals Co Ltd is 59.16 CNY with a low forecast of 58.58 CNY and a high forecast of 60.9 CNY.

Lowest
Price Target
58.58 CNY
9% Downside
Average
Price Target
59.16 CNY
8% Downside
Highest
Price Target
60.9 CNY
5% Downside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for Suzhou Zelgen Biopharmaceuticals Co Ltd?

Click here to dive deeper.

Dividends

Suzhou Zelgen Biopharmaceuticals Co Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for Suzhou Zelgen Biopharmaceuticals Co Ltd is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Suzhou Zelgen Biopharmaceuticals Co Ltd Logo
Suzhou Zelgen Biopharmaceuticals Co Ltd

Country

China

Industry

Biotechnology

Market Cap

17B CNY

Dividend Yield

0%

Description

Suzhou Zelgen Biopharmaceuticals Co., Ltd. engages in the innovation, research, development, manufacturing, and commercialization of new medications. The company is headquartered in Suzhou, Jiangsu and currently employs 688 full-time employees. The company went IPO on 2020-01-23. The firm's main technology platforms include precision small molecule drugs R & D and industrialization platform and complex recombinant protein drug development and industrialization platform. The firm's R & D product pipelines include Donafenib, Recombinant human thrombin for topical use, Jaktinib hydrochloride tablets, Alkotinib, Recombinant human thyroid stimulating hormone for injection, Jaktinib hydrochloride cream, ZG5266, ZG0588, ZG170607, double Specific antibodies ZG005 and ZG006. The firm also provides R & D and clinical trial drug production and processing services. The firm operates its businesses primarily in Mainland China.

Contact

JIANGSU
Suzhou
No. 262, Chenfeng Road, Yushan Town, Kunshan City
+8651257018310
www.zelgen.com

IPO

2020-01-23

Employees

688

Officers

Chairman of the Board & GM
Mr. Zelin Sheng
CFO & Deputy GM
Mr. Gang Huang
Chief Scientific Officer
Ms. Zeqi Sheng
Executive Deputy GM & Director
Ms. Huiping Lu
Director & Deputy GM
Mr. Jisheng Wu
Deputy General Manager & Director
Mr. Binhua Lv
Show More
Deputy GM & Board Secretary
Ms. Qingping Gao
Show Less

See Also

Discover More
What is the Intrinsic Value of one Suzhou Zelgen Biopharmaceuticals Co Ltd stock?

The intrinsic value of one Suzhou Zelgen Biopharmaceuticals Co Ltd stock under the Base Case scenario is 57.58 CNY.

Is Suzhou Zelgen Biopharmaceuticals Co Ltd stock undervalued or overvalued?

Compared to the current market price of 64.04 CNY, Suzhou Zelgen Biopharmaceuticals Co Ltd is Overvalued by 10%.

Back to Top